Chemdex: The B2B Lab Experiment

The latest buzzword on the Net, of course, is B2B (business-to-business).
So, what is a B2B company? Simply put, it allows businesses to transact
with each other — in virtually any industry, such as chemicals, steel,
plumbing and so on.

B2B appears to be the so-called “Next Big Thing.”
Actually, I think this is understating the situation. A more apt
description would be “The Next Huge Thing.”

For example, according to a recent report from Goldman Sachs, the B2B
industry is expected to generate $115 billion this year. By 2004, this is
forecasted to explode to $1.5 trillion.

Unfortunately, there are not many B2B companies to select from. Here is a
chart:

What is very interesting about this list is that ICGE — which is an
incubator for B2B companies — has a higher market capitalization than CMGI.
Then again, B2B is expected to far outpace the business-to-consumer online
market.

Although, there are traditional companies that are, in a sense, becoming
B2B powerhouses, such as Cisco, Oracle and Dell Computer — all of which
are doing tremendous amounts of business through their extranets.

But let’s focus on the pure B2B plays.

One that looks promising is
Chemdex (CMDX). The
company is known as a B2B “market maker,” specializing on the life-sciences
space.

Basically, this means the company brings buyers and sellers together
in a centralized environment to buy such things as biological and chemical
reagents, instruments and lab supplies.

The company has two main products: Science360 and LabPoint. These
technologies allow for contract pricing, consolidated ordering and
reordering, customized supplier lists, automated approval workflow and ERP
integration. Also, each product has detailed content and can be easily
searched.

Chemdex solution relies on Net standards and is relatively easy to install
and maintain. In fact, the technology integrates with top B2B solutions,
such as those from Commerce One and Ariba.

Traditionally, it has been scientists who have purchased life sciences
equipment. Unfortunately, the process was highly inefficient, relying on
paper catalogs and phones.

Such fragmentation was a tremendous opportunity for Chemdex — with the
market for life science research products estimated to be about $9.4
billion in 1998.

And it is a growing market — driven by new fields such as genomics,
combinatorial chemistry and other exotic disciplines.

So far, Chemdex has created a substantial life sciences hub, with a
database of over 225,000 products.

On September 22, Chemdex purchased Promedix.com. With the acquisition,
Chemdex will have access to 260,000 medical supply items (from 500
suppliers) for such things as catheters and pacemakers. The price of the
acquisition was $334 million in stock.

Interestingly enough, the largest biotech trade organization — the
Biotechnology Industry Organization — has endorsed the Chemdex solution.

Chemdex has also attracted the financial endorsements from major backers,
such as Kleiner Perkins and CMG@Ventures.

The life sciences business can be time-consuming and expensive. As for
Chemdex, it offers researchers a compelling solution. As for marketers of
equipment, they have a targeted market. In other words, Chemdex is a
classic win-win. And it should be a win-win for investors, as well.

ALL NEW! internet.com’s HotWatch a monthly e-mail subscription for $99,
featuring Internet Stock Report’s top 10 noteworthy Internet stocks for the
month. Each month you will receive in-depth analysis on the top 10 Internet
stocks to watch with the information you need to assess the fast-paced nature
of Internet stocks. Staying on top of market changes in the Internet Stock
market is what counts. For $99 per year, you receive 12 timely issues sent to
you by e-mail. Don’t wait, our next issue will be out before you know it with a
whole new
perspective on the market. Sign up today at: e-newsletters